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The microbiome is a complex community of Bacteria, Archaea, Eukarya, and viruses that infect hu-
mans and live in our tissues. It contributes the majority of genetic information to our metagenome
and, consequently, influences our resistance and susceptibility to diseases, especially common
inflammatory diseases, such as type 1 diabetes, ulcerative colitis, and Crohn’s disease. Here we
discuss how host-gene-microbial interactions aremajor determinants for the development of these
multifactorial chronic disorders and, thus, for the relationship between genotype and phenotype.
We also explore how genome-wide association studies (GWAS) on autoimmune and inflammatory
diseases are uncoveringmechanism-based subtypes for these disorders. Applying these emerging
concepts will permit a more complete understanding of the etiologies of complex diseases and
underpin the development of both next-generation animal models and new therapeutic strategies
for targeting personalized disease phenotypes.Recent advances in diverse areas of science and technology
make this a unique time to study the genetics and pathogenesis
of complex diseases, such type 1 diabetes (T1D) and inflamma-
tory bowel disease (IBD), which includes Crohn’s disease (CD)
and ulcerative colitis (UC). These distinct diseases are now
understood to share important common characteristics and
aspects of their disease mechanisms. In all three diseases, the
immune system damages tissues: T1D is likely an autoimmune
disease, whereas CD and UC are likely caused by inappropriate
inflammatory responses to components of our microbiome (see
Box 1 for definition of key terms). Many genetic loci regulate the
risk for each disease. Although a threshold dose of these
susceptibility alleles provides the foundation for developing the
disease, these alleles are not sufficient to cause the disease.
It has been obvious for decades that complex gene-gene and
gene-environment interactions govern these diseases, but not
surprisingly, untangling this web of interactions has been
extremely difficult (Figure 1). Despite the failure to identify single
causal agents for each disease, there is strong evidence that
microbes contribute to pathogenesis. Furthermore, genome-
wide association studies (GWAS), which use large study popula-
tions and careful replication of results, have effectively identified
many important loci in the host that increase one’s risk for the
disease, and these results have fundamentally altered how we
conceptualize these diseases (Stappenbeck et al., 2011; Khor
et al., 2011; Anderson et al., 2011; Franke et al., 2010; Todd,
2010). Correlation of GWAS data with genome-wide gene
expression analyses (eQTLs), in combination with protein-
protein interaction data, is greatly assisting the identification of
candidate causal genes within these loci (Anderson et al.,
2011; Franke et al., 2010; Cotsapas et al., 2011; Rossin et al.,
2011; Fehrmann et al., 2011). Recently, numerous approaches44 Cell 147, September 30, 2011 ª2011 Elsevier Inc.have been developed to start defining mechanisms for complex
inflammatory diseases by using leads from GWAS and analyses
of the microbiome. These promising approaches include the
following: the introduction of mutations in GWAS-identified loci
into the mouse genome (Cadwell et al., 2010; Bloom et al.,
2011); the creation of induced pluripotent stem cells (iPSCs)
from patients and their differentiation into relevant cell types
(e.g., Rashid et al., 2010); and humanized mouse models in
which the murine immune system is replaced by transplantation
(e.g., Brehm et al., 2010; Esplugues et al., 2011) or humanmicro-
bial communities are transplanted into formerly germ-free mice
(Goodman et al., 2011). Currently the great challenges in this field
are to (1) understand how both microbiome and GWAS-identi-
fied genes contribute to disease; (2) elucidate the molecular
mechanisms by which causal genes act during pathogenesis;
and (3) validate biomarkers and druggable pathways via geno-
type-phenotype studies (e.g., Dendrou et al., 2009; Bloom
et al., 2011; Cadwell et al., 2010).
By peering through the lens of recent studies on CD, UC, and
T1D, this review seeks to delineate emerging concepts in
research on complex inflammatory diseases and to comment
on the implications of these concepts for the interpretation of
genetic and pathogenetic data. Two concepts are emphasized
and integrated herein: (1) that single disease diagnoses are
unlikely to be single phenotypes and may instead be the sum
of multiple mechanism-based disease subsets, and (2) that the
interactions of individual microorganisms and their genomes
with specific host genes or pathways underpin the relationship
between genotype and phenotype in these complex diseases.
In this view, disease geneticsmay be combinatorial with different
host-gene-microbial interactions, contributing to the pathogen-
esis of disease in subsets of patients. These two interrelated
Box 1. Definition of Terms
Dysbiosis: Most commonly refers to a disruption in the normal
homeostatic and beneficial relationship between microbes and their
host, including disruptions in microbial community structure and
function. Alterations in microbial community structure, involving
Bacteria, Archaea, and/or Eukarya, can occur in any body habitat
but have been best described in the gut where they have been asso-
ciated with a number of disease states including, for example, inflam-
matory bowel disease.
GWAS: Analysis of common alleles (mostly single-nucleotide poly-
morphisms, SNPs) in a population that associates genetic loci with
disease susceptibility. These loci contain ‘‘candidate’’ disease genes.
Familial clustering: If a family member is diagnosed with a disease
such as type 1 diabetes, ulcerative colitis, or Crohn’s disease, then
the risk of other first-degree family members is much greater
(perhaps as much as 50-fold for some multifactorial disorders) than
that for a person taken at random from the general population.
Familial clustering is caused by a combination of inherited genetic
variants from the parents to the children and shared environmental
factors within the families. Susceptibility variants are being discov-
ered rapidly by GWAS, but the environmental factors remain
unknown, although numerous candidates are recognized, most
particularly a role for the microbiome and infections.
Metagenetics: Approaching genetic and genomic studies by
considering all of thegenes in themetagenomeasopposed toconsid-
ering, in isolation, host genes or genes that confer particular proper-
ties (e.g., virulence or commensalism) upon an individual microbe.
Importantly, the history of microbial inputs into the metagenomic
profile of an individual is important for identifying the causes of
complex disease, requiring expensive but essential longitudinal
studies, including information from maternal and gestational expo-
sures and phenotypes.
Metagenome: As used here, metagenome is the sum of all genes
and genetic elements and their modifications in the somatic and
germ cells of a host plus all genes and genetic elements in all micro-
organisms that live on or in that host at a given time. The metage-
nome has transient elements (e.g., during infection with a pathogen)
and more persistent elements (e.g., infection with latent eukaryotic
virus; presence of commensal bacteria).
Microbiome: As used here, the microbiome is the sum of all micro-
bial organisms that live in or on the host at a given time. The micro-
biome includes members of Bacteria, Archaea, Eukarya, and the
viruses of these organisms. In other articles this term may be used
to refer to the genes of these organisms.
Virome: The sumof all viruses living in the tissues of the host or infect-
ingorganisms in themicrobiome.Thesevirusesmaybe furtherdivided
into viruses that infect members of each of the three domains of life
(e.g., bacterial virome or bacterial phages or the eukaryotic virome).concepts, therefore, define T1D, CD, and UC as metagenetic
(Box 1), rather than simply ‘‘genetic,’’ diseases. These concepts
will guide the design and interpretation of future experiments that
seek to dissect the pathophysiologic mechanisms underlying
a number of complex diseases and to identify more effective
approaches for their treatment and prevention.
Host Genetic Grist for the Metagenetic Mill
Recently, meta-analyses of GWAS of large cohorts of patients of
European descent with UC or CD have been performed (Franke
et al., 2010; Anderson et al., 2011; Khor et al., 2011). Thesestudies identified 98 loci, and candidate genes within these
loci, that have a putative role in IBD. Similar studies of T1D iden-
tified 53 disease susceptibility loci (Barrett et al., 2009) (http://
www.t1dbase.org). Importantly, many disease susceptibility
loci are shared among common autoimmune and inflammatory
diseases, including T1D, Graves’ disease, celiac disease, CD,
UC, psoriasis, rheumatoid arthritis, alopecia areata, multiple
sclerosis, and systemic lupus erythematosus (Cotsapas et al.,
2011; Khor et al., 2011). It is striking that T1D and CD share
13/52 (25%) risk loci outside the human leukocyte antigen
(HLA) gene complex despite the fact that these diseases are
neither thought to be related diseases nor reported to be shared
within families more often than expected by chance (http://www.
t1dbase.org). Notably, the candidate causal genes in these 13
susceptibility loci regulate immunity. These include (Khor et al.,
2011) PTPN22, which is involved in T and B cell signaling; IL10,
encoding a powerful cytokine that suppresses inflammatory
responses (including in specialized T regulatory cells in the gut)
(Maloy and Powrie, 2011); BACH2, which regulates B cell
gene expression and possibly IgA production; TAGAP, which
is involved in T cell activation; IKZF1, which negatively
regulates B cells; IL2RA, which controls T regulatory lymphocyte
development and function; GSDMB/GSDMA/ORMDL3, which
is involved in stress responses; FUT2, which controls micro-
bial susceptibility (Smyth et al., 2011; Franke et al., 2010;
McGovern et al., 2010); and IL27, which suppresses inflamma-
tory responses and regulates IL-10 signaling (Imielinski et al.,
2009; Barrett et al., 2009). This is a remarkable concordance of
involved genes for two unrelated diseases, indicating that
different diseases can have common mechanistic components
and that the immune system is key for both diseases.
However, not withstanding all insights into disease mecha-
nisms that the GWAS approach has already provided, the inher-
itance and the strong clustering of these multifactorial diseases
within families (Box 1), which encompass both inherited genetic
variants and intrafamilial environmental factors, remain only
partially explained. Assuming a simple statistical model of
gene interaction (Clayton, 2009), the numerous identified loci
account for not more than 25% of the familial clustering of CD
and UC (Anderson et al., 2011; Franke et al., 2010). This
contrasts with T1D, in which the HLA effect is uniquely large
and, together with 52 non-HLA loci, can account for almost all
of the familial clustering (Clayton, 2009). For T1D, the massive
effect of the HLA region, owing to functional polymorphisms in
the HLA class II and class I genes, contributes almost 50% of
familial clustering on its own (Clayton, 2009; Todd, 2010). There
are, however, probably hundreds of non-HLA loci affecting the
risk of CD, UC, and T1D that remain unmapped owing to their
very small effect sizes (Barrett et al., 2009; Anderson et al.,
2011; Franke et al., 2010). These putative loci will be difficult to
map unless they contain rare mutations of higher penetrance,
an occurrence that is just beginning to yield informative findings
(Nejentsev et al., 2009; Rivas et al., 2011) and holds continued
promise with the rapid use of high-throughput next-generation
sequencing.
In humans, the HLA locus contains a large number of genes
encoding themajor histocompatibility complex (MHC)molecules
(which are responsible for presenting antigens to cells of theCell 147, September 30, 2011 ª2011 Elsevier Inc. 45
Figure 1. Perfect Storms for Developing Crohn’s Disease and Type 1 Diabetes
A series of overlapping events and phenotypes driven by metagenetic and environmental processes that, in sum, contribute to the development and patho-
genesis of type 1 diabetes (A) and Crohn’s disease (B).immune system), along with a number of other genes that modu-
late immune responses. The remarkable contribution of HLA
variations (Todd, 2010) to T1D risk is an unusual feature of a
common disease. Nevertheless, HLA genotypes that greatly
predispose individuals to T1D are not sufficient to cause the
disease because only 5% of high-risk HLA carriers develop
T1D. HLAs are expressed by antigen-presenting cells (APCs),
such as macrophages, B lymphocytes, and dendritic cells
(DCs). DCs are highly potent APCs that reside in the pancreas
and its islets (i.e., collections of insulin-producing beta cells
and other endocrine cells) and could initiate the autoimmune
destruction of beta cells by T cells (Calderon et al., 2011a,
2011b). Interestingly, the pancreatic lymph nodes, where DC
priming of T cells for the induction of T1D may occur, also drain
parts of the intestine, providing a site where the microbiome
might influence the genesis of T1D (Turley et al., 2005; Wen
et al., 2008). Because the insulin gene is one of the strongest
non-HLA T1D susceptibility loci in the genome (Todd, 2010)
(http://www.t1dbase.org), insulin and its precursors are likely
primary autoantigens. These very strong associations with both
HLA and this autoantigen gene are not a feature of CD or UC,
in which no particular antigen is known to be targeted, hence
their classification as inflammatory rather than autoimmune
diseases. GWAS point to several other immunologic compo-
nents of T1D etiology, including IL-2 production and receptor
signaling (IL-2 gene, IL-2 receptors IL2RA [CD25] and IL2RB
[CD132]; Todd, 2010), immune tolerance and T cell receptor
signaling (PTPN2 [Long et al., 2011], PTPN22 [Arechiga et al.,
2009; Bottini et al., 2006]), and recently, the immune response
to viral infections and the type 1 interferon responses (IFIH1
[encoding MDA5], GPR183 [EBI2] [Heinig et al., 2010], TLR7
and TLR8, and FUT2 [Smyth et al., 2011]).46 Cell 147, September 30, 2011 ª2011 Elsevier Inc.Twenty-eight loci (28/71, 39%) of CD risk loci are shared with
UC, indicating that a set of core mechanisms participate in these
diseases (Figure 2) (Khor et al., 2011). These diseases genes
implicate numerous processes in both CD and UC, including
T cell differentiation and function, autophagy, endoplasmic retic-
ulum stress, oxidative stress, and mucosal immune defenses,
among others. There are important gene-gene and pathway-
pathway interactions within this core set of processes. For
example, the CD risk gene NOD2 links to autophagy through
interactions with the Nod2 protein and with Atg16L1, induction
of proinflammatory cytokines, control of bacterial infection,
and sensing of pathogen-associated molecular patterns (Levine
et al., 2011). Particularly notable are pathways involving the
cytokines IL-23 and IL-12, which regulate the development of
TH1 and TH17 CD4 T cells, and IL-10, which is essential in the
function of certain regulatory T cells (Tregs) via its anti-inflamma-
tory activity. Rare mutations in genes encoding IL-10 receptors
confer susceptibility to early-onset IBD (Glocker et al., 2009).
These genetic clues point to a key role for regulating the balance
between pro- and anti-inflammatory T cells in CD and UC. The
regulation of T cell differentiation is also a key target for host-
gene-microbial interactions, as discussed below.
Mechanism-Based Disease Subtypes
GWAS have revealed a wealth of genes potentially involved in
T1D, UC, and CD, but no single gene or set of genes is prog-
nostic. How can we interpret this observation? Here, we argue
for an important contributor to this observation—the concept
that ‘‘diagnosis’’ does not equal ‘‘single phenotype.’’ Without a
distinct phenotype, genetic results are often difficult to interpret.
This basic principle comes into sharp focus as one considers
current genetic and pathogenesis studies of CD, UC, and T1D.
Figure 2. Refining the Relationship between Genotype and Pheno-
type in Complex Inflammatory Diseases
(A) Traditionally, a disease is considered as a single phenotype, with genes or
loci conferring risk to two diseases shown as overlapping in a Venn diagram.
(B) We propose a new view of the genotype-phenotype relationship in which
different sets of loci are responsible for mechanistically distinct subtypes of
diseases, and the sum of these subtypes constitutes the overall diagnosis.
Here two disease subtypes are indicated for simplicity, but many such
subtypes may exist, and sets of overlapping risk loci may be associated with
these multiple mechanistically distinct disease phenotypes.Why is a diagnosed ‘‘disease’’ an imprecise phenotype? It is
not because patients have been misdiagnosed—the diagnoses
of UC, CD, or T1D have stood the test of time to predict patient
prognosis. However, we believe that there aremany pathways to
the same diagnosis. A diagnosis may be ‘‘clinically’’ precise but
‘‘mechanistically’’ imprecise. Thus, clinical diagnoses are poor
phenotypes for genetic studies unless a single mechanism is
responsible for the diagnosis, as in the case of a rare gene muta-
tion in a monogenic disease. The complexity of GWAS results is
consistent with the existence of multiple disease subtypes within
T1D, UC, or CD, each based on a specific mechanism (Figure 2).
Support for this idea comes from the observation that subsets of
IBD patients respond differentially to mechanistically distinct
interventions (Melmed and Targan, 2010).
Why do diagnostic categories group different mechanistic
processes under the same moniker? Over many decades,
pathologists have lumped patients with similar but nonidentical
clinical and pathological signs and symptoms into diagnostic
categories that predict outcome and complications. Indeed,
this has enormous value clinically, but it emphasizes similarities
between patients in outcome rather than differences in pathways
that lead to a common endpoint. Complex diseases are diag-
nosed by summing up multiple factors that may be causes or
mere consequences of the disease process. Disease ‘‘diag-nosis’’ does not require the presence in the tissue of all of the
abnormalities that may be ‘‘classically’’ seen in a given disease
(Gianani et al., 2010; Odze, 2003). For example, at the polar
extreme, CD is easily distinguished from UC by its classical ileal
involvement (i.e., involvement of tissue at the end of the small
intestine), fissures, granulomas, transmural inflammation (i.e.,
inflammation through the entire intestinal wall), fat wrapping of
the intestine, patchy pathology, skip lesions, and patient presen-
tation with bowel strictures or percutaneous fistulae. However,
like UC, CD can be restricted to the colon, and the inflammatory
infiltrates of CD and UC overlap. UC can be patchy, and the
patient presentations of the two diseases can overlap exten-
sively. Similarly, the genetics, pathology, and pathogenesis of
IBD may differ between young and old patients with the same
diagnosis (Imielinski et al., 2009; Odze, 2003). Even when all
classical aspects of a disease are present, the mechanism re-
sponsible for the pathology observedmay differ from one person
to another. Based on these considerations, it is no surprise that
the genetics of T1D, CD, and UC are complex because different
phenotypes may have been grouped into a single analysis.
This putative mechanistic heterogeneity is reflected in some-
times subtle, but quantifiable, characteristics of the disease pro-
cess and pathology. Taking such differences into account can be
used to identify disease subtypes that are more recognizable as
molecularly defined pathological conditions and that more
closely relate to specific pathogenetic mechanisms underpinned
by distinct sets of genetic risk loci (Figure 3). For example, vari-
ations in the ATG16L1 gene (i.e., hypomorphic expression in the
mouse and homozygosity for the T300A variant in humans) result
in abnormalities in Paneth cell granules and secretion (Cadwell
et al., 2008, 2010). Paneth cells are innate immune epithelial cells
positioned at the base of small intestinal crypts, where they
secrete antimicrobial peptides and other factors that help shape
the configuration of the intestine’s bacterial community. Abnor-
malities in Paneth cells are observed in the subset of CD patients
homozygous for the T300A allele, thus defining a pathologic
subtype of CD (Figure 2B). If one used criteria including Paneth
cell abnormalities in CD diagnosis, the frequency of the
ATG16L1 T300A allele would be higher in patients with the ‘‘Pan-
eth cell subtype’’ of CD than in the CD population as a whole
(Figure 3). If multiple risk loci contribute to such Paneth cell
changes, one might be able to detect gene-gene interactions
in this subset of patients compared to other subsets.
A similar situation exists in T1D. Biopsy specimens of the
pancreas are virtually impossible to obtain. Therefore, T1D is
defined clinically by the downstream consequences of destroy-
ing the insulin-secreting b cells of the pancreatic islets, namely,
high blood glucose and absolute insulin dependence, rather
than by the mechanisms for their destruction. It is, therefore,
possible that several different pathologic processes result in
this disease. T1D patients diagnosed under age 10 years
frequently exhibit islet inflammation or insulitis, whereas patients
diagnosed over age 10 years exhibit insulitis less frequently.
More recently, this histopathological heterogeneneity has
become even more evident (Gianani et al., 2010), thanks to the
Juvenile Diabetes Research Foundation nPOD project (http://
www.jdrfnpod.org). As for CD, the diagnosis of T1D may reflect
the presence of more than one pathogenetic mechanism and,Cell 147, September 30, 2011 ª2011 Elsevier Inc. 47
Figure 3. The Iterative Redefinition of Mechanism-Based Disease
Subtypes
Here we present a conceptual workflow for breaking a broad disease diag-
nosis into its component subtypes by the iterative application of genetics and
mechanistic studies. One output would be therapeutics based on disease
subtype and patient stratification into groups more likely to respond to a given
therapy or preventive strategy (A). (B) shows specific challenges for this
process for type 1 diabetes and Crohn’s disease.thus, represent more than one disease subtype, although in T1D
the HLA effects are an essential common pathway.
The concept that disease diagnoses include mechanism-
based disease subtypes has many implications for interpreting
human genetic studies and for understanding the relationship
between the microbiome and genetic susceptibility, as dis-
cussed below. Including disease subtypes within a single diag-
nosis would decrease the power to define causal alleles and to
detect gene-gene interactions that contribute to a single disease
subtype. In this view, the difficulty of interpreting how multiple
small genetic effects sum to predispose an individual to a clinical
diagnosis may partly reflect insufficient precision in selection of
specific phenotypes to study.
It is important to recognize that it is the power and informative-
ness of GWAS themselves that drive the concept of mechanism-
based disease subtypes (Figure 2). In the absence of candidate
genetic mechanisms for defining disease subtypes, there is
limited clinical utility in focusing on low-frequency characteristics
or subtypes within a larger diagnostic category that predicts48 Cell 147, September 30, 2011 ª2011 Elsevier Inc.patient outcome.We, therefore, argue for iterative high-precision
phenotyping of patients into mechanism-based subtypes in
future studies; this will allow more accurate interpretation of
genetic, pathogenesis, outcome, and therapeutic studies (Fig-
ure 3). Such definitions must be iteratively reassessed as risk
alleles are defined and disease mechanisms are delineated
so that the field is not limited by inflexible definitions of
disease that may obscure mechanistic heterogeneity. This type
of approach is a necessary presage to so-called stratified or
personalized medicine. The genetic and pathological complexity
of T1D, CD, and UC is particularly well suited for testing whether
iteratively redefining disease diagnoses can enhance the value of
genetic and pathogenesis studies. Importantly, precision in
disease categorization would make defining the impact of host-
gene-microbial interactions on disease processes more robust.
Host-Gene-Microbial Interactions in Metagenetics
Metazoan organisms are complex communities that include a
core organism in combination with a veritable zoo of other organ-
isms that live on or in the body—our microbiome. The micro-
biome includes eukaryotic viruses, Eukarya, bacteria viruses,
Bacteria, Archaea, and, for many, helminths (Virgin et al., 2009;
Kau et al., 2011; Garrett et al., 2010b; Spor et al., 2011). The
importance of understanding the microbiome has been repeat-
edly emphasized, giving rise to a large number of international
human microbiome projects (e.g., https://commonfund.nih.
gov/hmp/, http://www.metahit.eu/) that have focused initially
on the bacterial component of the microbiome. The host plus
non-host genes of this polyglot and interactive community
constitute our metagenome (Box 1). A critical emerging concept
is that bacterial and viral interactions in the pathogenesis of
inflammatory disease occur in a host gene-specific fashion
(see below; Virgin et al., 2009; Cadwell et al., 2010; Bloom
et al., 2011; Elinav et al., 2011). Understanding the metagenome
is, therefore, highly relevant to understanding T1D, UC, CD, and
other common multifactorial diseases.
Intestinal bacteria play a role in driving IBD, and emerging data
support a similar view for T1D (Wen et al., 2008; Giongo et al.,
2011; Roesch et al., 2009). The evidence that bacteria play
a role in IBD includes twomajor observations: that surgical diver-
sion of the fecal stream ameliorates inflammation (Sartor, 2008),
and that antibiotics help some patients. In mouse models of
colitis, viruses, bacteria, or both acting together can contribute
to the pathology via signaling through innate immune sensors
and regulation of pro- and anti-inflammatory cytokines (Levine
et al., 2011; Maloy and Powrie, 2011; Khor et al., 2011). For
many years, enterovirus infection has been associated with
T1D (e.g., Yeung et al., 2011; Oikarinen et al., 2011; Stene
et al., 2010), and the major sensor for enterovirus RNA is the
T1D susceptibility gene IFIH1, encoding MDA5 (Nejentsev
et al., 2009; McCartney et al., 2011). The mechanisms for these
associations between components of the microbiome and T1D,
CD, or UC have proven elusive. The lack of integration among
scientific disciplines and among training programs, together
with limitations in technology, has substantially limited the
understanding of metagenomic contributions to disease.
Adult mammals are permanently infected by many viruses,
and they are populated by large site-specific bacterial and
Figure 4. Microbe Plus Gene Interactions Determine Inflammatory Bowel Disease Phenotypes
(A) Two recent studies analyzed the capacity of two different strains of murine norovirus, MNV strain CR6 versus MNV strain CW3, to trigger phenotypes when
orally inoculated into mice with a mutation in the Crohn’s disease risk gene Atg16L1 (Cadwell et al., 2008, 2010). This mutation results in decreased expression of
Atg16L1 protein (hypomorphic, Atg16L1HM). Even though MNV CW3 and MNV CR6 are closely related, they have different effects on intestinal pathology in
Atg16L1HM mice. Some of these interactions are observed only when mice are fed the chemical dextran sodium sulfate (DSS).
(B) Two other studies analyzed the capacity of two different species of Bacteroides to trigger phenotypes in combination with mutations in the IL-10 receptor and
T cell expression of a dominant-negative form of the TGF-b receptor (dnKO mice) (Bloom et al., 2011; Kang et al., 2008). dnKO mice are cured of their spon-
taneous colitis by treatment with antibiotics, but oral feeding of ‘‘cured’’ mice with fecal contents or specific bacteria reinduces disease. Even thoughBacteroides
thetaiotaomicron and Bacteroides sp. TP5 are closely related, they induce different forms of inflammation when fed to antibiotic-cured dnKO mice. In the same
studies, dysbiosis (Box 1) with increases in the numbers of Enterobacteriaceaewas noted in dnKOmice prior to curing the mice with antibiotics. However, E. coli
inoculation did not trigger the pathologies seen with either Bacteroides species.phage communities without overt negative effects (Virgin et al.,
2009; Foxman and Iwasaki, 2011; Spor et al., 2011). Thus, the
bacterial microbiota (and their phages) and the eukaryotic vi-
rome are two major (but not the only) contributors to the meta-
genome. The intestinal microbiome plays a critical role in
mammalian physiology by synthesizing vitamins and harvesting
energy from food (Spor et al., 2011; Kau et al., 2011). Further,
the normal function of the innate immune system, which is crit-
ically involved in the pathogenesis of T1D, UC, and CD, is regu-
lated by both chronic viral infections and resident bacterial
communities (Barton et al., 2007; White et al., 2010; Virgin
et al., 2009; Spor et al., 2011; Kau et al., 2011). The microbiome
and metagenome vary from person to person based on host
genetics, diet, exposure, geography (including westernization
as approximated by the gross national product of a country),
socioeconomic status, mode of delivery, gestational age at
birth, breast feeding, antibiotic use, and additional factors
(Virgin et al., 2009; Benson et al., 2010; Spor et al., 2011; Kau
et al., 2011; Penders et al., 2006). Such variations could certainly
provide environmental inputs that contribute to the incidence
of T1D, UC, and CD, within the genetic foundation revealed byGWAS (Bach, 2002; Vehik and Dabelea, 2011; Ehlers and Kauf-
mann, 2010).
There are extensive interactions between host and non-host
genes within the metagenome, and bacteria and eukaryotic
viruses alter our physiology and fitness (Spor et al., 2011; Virgin
et al., 2009; Hansen et al., 2010). These genetic interactions
within themetagenome create a complex and poorly understood
host-gene-microbial interaction matrix that can define pheno-
type. Host genes, such as those involved in innate and adaptive
immunity (e.g., NOD2, NLRP6, HLA, TLR2, and MYD88), shape
the bacterial microbiota (Spor et al., 2011; Elinav et al., 2011;
Wen et al., 2008). Forward genetic screens in mice suggest
that resistance to individual viruses involves hundreds of genes
(Virgin et al., 2009), making it likely that many host genes regulate
the microbiome (and thus the metagenome). Importantly, key
interactions between members of the microbiome have been
and are increasingly being reported. For example, murine noro-
virus can trigger an intestinal inflammatory process in mice with
a mutation in Atg16L1. This process can be treated with antibi-
otics and is thus presumed to be bacteria dependent (Cadwell
et al., 2010) (Figure 4). The existence of such interactionsCell 147, September 30, 2011 ª2011 Elsevier Inc. 49
Figure 5. A Metagenetic View of Develop-
ing Normal and Pathological Immune
Responses
This flowchart depicts stages in the development
of normal immune responses or autoimmune
and inflammatory diseases at which metagenetic
interactions (i.e., gene-gene and gene-microbe
interactions) might play a determining role.
‘‘Microbial products’’ refers to molecules that
interact with host innate immune sensors and
initiate inflammation.indicates that it will be important to consider that the disease
contributions of microbiome members (e.g., helminths and
bacteria) are potentially dependent on each other.
Metagenetic influences on disease could occur in various
ways. Familial disease clustering may reflect intrafamilial behav-
ioral and dietary factors that define the metagenome. A major
influence on the human metagenome may be vertical transmis-
sion of the maternal microbiome. In the controlled environment
of mouse colonies, the bacterial microbiota is clearly maternally
inherited. Furthermore, this microbiome can have profound
pathological effects in mice carrying specific mutations, such
that studies of host-gene functions must now consider contribu-
tions of the metagenome (see below).
The situation in humans is more complex (Hansen et al., 2011;
Benson et al., 2010), although the importance of early environ-
mental exposures has been well documented, including studies
withmono- and dizygotic twins (Turnbaugh et al., 2009). Children
delivered vaginally initially acquire a distinctly different intestinal
bacterial microbiota than those born by caesarian section (Pen-
ders et al., 2006; Dominguez-Bello et al., 2010). In a meta-anal-
ysis, delivery by caesarean section increases the risk of T1D by
20% (Cardwell et al., 2008). An association with increased risk
for T1D has also been reported for higher birth weight (Cardwell
et al., 2010) and early infant diet (Pflu¨ger et al., 2010) (Figure 5).
Furthermore, changing microbial exposures and infections likely
has a major influence on the incidence of other diseases. The
dramatic rise in the incidence of allergy, asthma, and T1D in
the last 60 years correlates with vast improvements in healthcare
and sanitation (Bach, 2002; Vehik and Dabelea, 2011; Ehlers and
Kaufmann, 2010). For example, severe rhinovirus infection
before the age of 3 years coupled to an asthma-predisposing in-
herited host genome, has been associated with increased risk
of asthma (Foxman and Iwasaki, 2011). Thus, the metagenome50 Cell 147, September 30, 2011 ª2011 Elsevier Inc.could contribute to disease susceptibility
and potentially explain a proportion of the
familial clustering, the so-called ‘‘missing
heritability’’ of multifactorial diseases.
Metagenetic Effects on Immunity
and Autoimmunity
GWAS point to a fundamental role for
the immune system in the pathogenesis
of T1D, UC, and CD. An emerging con-
cept is that bacterial and viral interac-
tions contribute to both normal immune
physiologies and abnormal pathologicresponses that occur in a host gene-specific fashion (Virgin
et al., 2009; Cadwell et al., 2010; Bloom et al., 2011; Garrett
et al., 2007; Elinav et al., 2011). The microbiome has significant
effects on the development of the immune system (Lee et al.,
2011; Mazmanian et al., 2008; Sartor, 2008; Ivanov et al., 2009)
and on physiology, including susceptibilities to obesity and the
metabolic syndrome (Kau et al., 2011). Serum IgE responses to
antigenic challenge are lower in mice colonized withClostridium,
confirming that bacteria can have profound effects on systemic
immune responses involved in allergy (Atarashi et al., 2011).
Central nervous system (CNS) inflammation induced by autoan-
tigen is limited in germ-free mice, but it can be restored by
colonization with specific bacteria (Lee et al., 2011). In the
non-obese diabetic (NOD) mouse model mouse model, autoim-
mune diabetes is regulated by a MyD88-dependent interaction
of intestinal microbes with the innate immune system (Wen
et al., 2008). Germ-free K/BxN T cell receptor transgenic mice
are resistant to arthritis caused by autoantibodies to the self-
antigen glucose-6-phosphate isomerase. When these animals
are colonized with segmented filamentous bacteria (SFB), they
regenerate TH17 responses in the small intestine, autoantibody
production, and arthritis (Wu et al., 2010). Furthermore, the
normal intestinal microbiome is essential for effective resistance
to oral inoculation with Toxoplasma gondii and for generating
appropriate CD8+ T cell responses to influenza (Ichinohe et al.,
2011; Benson et al., 2009).
The mechanisms responsible for these observations are
under intensive investigation. One recent study shows that intes-
tinal bacteria induce Tregs in an antigen-specific and T cell
receptor-dependent fashion (Lathrop et al., 2011). This is a key
observation because it provides a mechanism, in addition to
thymic exposure to self-antigens, for how regulatory responses
can be generated to blunt inflammation. Given the continuous
presence of the stimulating antigens for these Tregs in the
normal intestinal microbiome, such cells could have profound
effects on both intestinal and systemic immune responses,
including responses to self-antigens. This is particularly im-
portant because it has been reported that T lymphocytes
migrate to the intestine to accept differentiation signals regu-
lating autoimmune responses (Esplugues et al., 2011). It was
also shown that injection of Staphylococcus aureus or its super-
antigen S. aureus enterotoxin B (SEB) was able to induce these
intestinal regulatory TH17 cells, which is consistent with SEB
injection being immune tolerogenic (Esplugues et al., 2011).
These studies suggest that variation in the metagenome
between individual humans, between mice in different research
facilities, or even between animals from different cages within
the same facility could have profound effects on many aspects
of the immune response. This concept has key implications for
the interpretation of mouse studies. The microbiome is mater-
nally inherited in mice, but it can differ among research facilities;
there may even be significant microenvironmental variation
between cages of mice or between mice born of different
dams. Given that the microbiome influences immunity so exten-
sively, experiments must control for these factors. Currently, this
is neither consistently performed nor required by peer reviewers.
Host-Gene-Metagenome Interactions in UC and CD
Correlations between communities of intestinal bacteria and CD
or UC have led to the concept of dysbiosis (Box 1) as a con-
tributor to these diseases (e.g., Sartor, 2008). This important
hypothesis emphasizes the potential role that changes in the
bacterial microbiota have on disease. However, now this hypoth-
esis needs to expand and include both nonbacterial components
of the metagenome and highly specific interactions between
individual bacteria or viruses and host genes, which have
recently been identified as contributors to disease pathogenesis.
The relative contribution of dysbiosis versus the contribution of
single organisms within the microbiome to the etiology of
complex inflammatory diseases is unresolved. A confounding
element has been the reliance on antibiotic treatment to assess
bacteria as causes for intestinal disease. Because antibiotics
can treat enteric inflammatory disease triggered by viruses
(Figure 4) (Cadwell et al., 2010), a broader approach—including
proof that specific bacteria or viruses are both necessary and
sufficient for a phenotype—will be required to understand meta-
genetics of disease. Specific risk alleles for CD or UC could
affect IBD by altering bacterial populations or individual bacterial
types (Maloy and Powrie, 2011; Garrett et al., 2010b; Spor et al.,
2011). Data from numerous mouse models of transmissible
colitis confirm this point and are discussed below. The
complexity of these reciprocal interactions between host and
non-host genes within the metagenome underlines the critical
need for new concepts and methodologies in computational
and systems biology that can deal with individual host-gene-
microbial interactions in the broader context of themetagenome.
IBD in humans and mice is associated with alterations in the
balance between TH1, TH17, and Treg cells, and this balance
is dependent on the metagenome (Garrett et al., 2010b; Maloy
and Powrie, 2011). The relevance of these studies to human
CD and UC is strongly supported by the identification of genesregulating these pathways in GWAS on IBD (see above). The
role of specific bacteria and helminths in regulating these T cell
responses in both the small and large intestine is highly relevant
to understanding the genetics and pathogenesis of IBD. Poly-
saccharide A synthesized by the common colonic commensal
Bacteroides fragilis induces Tregs that secrete IL-10 and inhibit
intestinal inflammation (Round and Mazmanian, 2010; Mazma-
nian et al., 2008). Similarly, a protein antigen secreted by the
intestinal helminth Heligmosomoides polygyrus induces Foxp3+
Treg cells in vitro and in vivo in mice (Grainger et al., 2010).
Furthermore, enteric carriage of a community of Clostridium
species induces IL-10-secreting Foxp3+ Tregs in the colon, likely
via induction of TGF-b (Atarashi et al., 2011). These findings are
interesting in light of the ubiquity ofBacteroides andClostridia as
commensal organisms in human and mouse, and differences in
human carriage of helminths across the world.
In mice, the presence of distant relatives of Clostridia, called
SFB, drives resistance to the enteric pathogen Citrobacter
rodentium and the induction of CD4+ TH17 cells in the lamina
propria of the small intestine (Ivanov et al., 2009; Gaboriau-Rou-
thiau et al., 2009). The discovery that SFB influence CD4+ T cell
differentiation was made when investigators noticed differences
in intestinal TH17 cell numbers between mice of the same strain
purchased from different vendors, followed by the demonstra-
tion that co-housing of these mice resulted in induction of
TH17 cells (Ivanov et al., 2009). SFB are highly evolved for their
commensal relationship with the mouse intestine (Sczesnak
et al., 2011). Similar organisms have not yet been reported in hu-
mans, but it seems likely that similarly coevolved organisms will
play a role in human intestinal biology and immunoregulation.
The discovery of the role for SFB in CD4+ T cell responses is
similar to the discovery of a virus-plus-gene trigger for an intes-
tinal disease in mice with symptoms similar to those in CD (Cad-
well et al., 2010). This finding occurred by comparing intestinal
phenotypes in one strain of mice bred in two different facilities.
Both of these findings underline the critical importance of directly
analyzing the contributions of the entire microbiome, rather than
individual components, in animal models of diseases.
Transmissible Colitis and Host-Gene-Metagenome
Interactions
Recent studies have made the striking observation that geneti-
cally determined colitis is transmissible, revealing a key role for
host genes in defining the microbiome and for metagenomic
contributions to enteric disease. Mice lacking both Rag2 and
the transcription factor T-bet develop colitis that can be trans-
mitted from amutant mother to wild-type fosterling mice (Garrett
et al., 2007, 2010a). Although there are expansions of specific
bacterial types in these mice, including Klebsiella pneumoniae
and Proteus mirabilis, another cofactor, in addition to these
bacteria, is required to generate the colitis phenotype. This co-
factor is not yet identified. Similarly,micedeficient inNLRP6, cas-
pase-1, IL-18, or ASC (all proteins that regulate the expression of
proinflammatory cytokines such as IL-18) develop colitis that is
transmissible to co-housed wild-type mice (Elinav et al., 2011).
Recent studies in another mouse model of transmissible
colitis, which has similarities to UC, provide an example of
the specificity of host-gene-bacterial relationships and IBDCell 147, September 30, 2011 ª2011 Elsevier Inc. 51
(Figure 4) (Bloom et al., 2011; Kang et al., 2008). Mice lacking the
IL-10 receptor and expressing a dominant-negative form of the
TGF-b receptor in T lymphocytes develop IFN-g- and TNF-a-
dependent colitis (Kang et al., 2008). The disease is cured by
antibiotic treatment and reinduced by co-housing diseased
and cured animals or by simply feeding cured mice the common
commensal bacteria Bacteroides thetaiotaomicron (B. theta)
(Bloom et al., 2011). In the same mice, the related Bacteroides
sp. TP5 induced a lymphocytic inflammatory infiltrate different
from that induced by B. theta, indicating the remarkable speci-
ficity of host-gene-bacterial interactions (Figure 4). The authors
noted dysbiosis in diseased animals with increased numbers
of Enterobacteriaceae, but these bacteria did not induce disease
despite being present in higher numbers in sick mice. This study
shows that a single bacterial type can cause IBD-like pathology
in the proper genetic setting, a bacteria-plus-gene interaction
that triggers intestinal inflammation. Importantly, the observation
that two closely related bacteria induce different pathologies in
the same genetically susceptible host provides support for the
concept that genes present in the non-host metagenome can
determine a host phenotype.
A similar observation, in this case of a virus-plus-gene interac-
tion that triggers IBD-like pathology, has been described in mice
mutant for the CD risk gene Atg16L1 (Figure 4) (Cadwell et al.,
2008, 2010). Abnormal Paneth cells were observed in humans
carrying the ATG16L1 T300A allele and mice hypomorphic for
expression of Atg16L1 raised in a conventional clean barrier
(Cadwell et al., 2008). Importantly, the phenotype of the mice
varied between different facilities and could be induced in
mutant mice, but not wild-type mice, by inoculation with
a specific strain of murine norovirus (Karst et al., 2003; Thackray
et al., 2007). When these mice were challenged with dextran
sodium sulfate (DSS), they developed inflammatory phenotypes
specific to the combination of Atg16L1 mutation and an indi-
vidual norovirus strain (Figure 4). Virus-triggered pathologies
could be treated by blocking TNF-a or IFN-g or by treatment
with antibiotics. Interestingly, infection with murine norovirus
enhances signaling through Nod1 and Nod2 via the induction
of type 1 IFN, potentially providing a direct link between enteric
viral infection and NOD signaling pathways implicated in IBD
risk (Kim et al., 2011). These data raise the possibility that
patterns of viral infection and specific components of the bacte-
rial metagenome act together to influence the penetrance of UC
and CD susceptibility risk alleles in humans. Furthermore, these
data show that closely related viruses can have quite different
effects on the phenotype of a host genetically prone to a disease
process. This finding further supports the concept that genes in
the non-host metagenome can determine host phenotypes.
Host-Gene-Metagenome Interactions in T1D
For T1D, recent observations fitwith a ‘‘perfect storm’’ scenario in
which numerous events combine to increase susceptibility to
disease development in early childhood (Figure 1). These events
include susceptibility alleles in HLA class II genes and INS that
cause increased autoreactivity against insulin, its precursors,
andother islet antigens; lowered IL-2, IL-10, and IL-27production
and signaling; altered T cell receptor signaling and regulation (via,
for example, susceptibility alleles in PTPN2, PTPN22, CTLA4,52 Cell 147, September 30, 2011 ª2011 Elsevier Inc.and IL2RA); and increased type1 IFNproduction and responsive-
ness (Todd, 2010; Robinson et al., 2011; Bluestone et al., 2010).
The ‘‘perfect T1D storm’’ is generated when these factors
combine with a permissive, modern environment of widespread
vitamin D deficiency (Cooper et al., 2011) and other still unidenti-
fied environmental factors (Figure 5). In particular, the T1D
susceptibility genes and candidates IFIH1 (Nejentsev et al.,
2009), GPR183 (EBI2) (Heinig et al., 2010), TLR7, TLR8 (Barrett
et al., 2009), and FUT2 (Smyth et al., 2011) strongly suggest an
etiological role for virus-induced, type 1 interferon production.
A common knockout mutation of FUT2 in several populations
causes the nonsecretor status (i.e., a lack of shedding of the A
and B blood group antigens into saliva and intestinal secretions).
This T1D-predisposing FUT2 genotype is also associated with
increased risk of CD (McGovern et al., 2010; Franke et al.,
2010), providing another direct mechanistic link between these
two diseases and microbial infections. The FUT2 nonsecretor
genotype is associated with resistance to certain strains of noro-
virus and Helicobacter pylori (Smyth et al., 2011). Investigations
of the mechanisms involved in the FUT2 associations with
chronic and infectious disease are urgently required, as is the
case for many of the newly identified GWAS candidate genes.
Defining the Metagenome Now and in the Future
Technologies for analyzing human loci involved in complex
diseases have, until recently, outstripped technologies for ana-
lyzing the metagenome. For example, single-nucleotide poly-
morphism (SNP)-based GWAS cover the entire human genome,
although at low resolution, whereas most common tools and
methods applied to the non-host metagenome focus on only
one component, such as a particular bacteria, viruses, or phage.
The non-host metagenome is so complex that researchers have
focused on DNA sequencing, even thoughmany organisms rele-
vant to disease—including enteroviruses that have been linked
to T1D and viruses that cause intestinal disease—have RNA
genomes. Although our knowledge of the human gut metage-
nome is in its infancy, this metagenome can now be explored
in detail by deep, next-generation sequencing of both RNA and
DNA, then stratified by host genotype, disease risk, or disease
status. Investigators are increasingly using shotgun sequencing
of RNA +DNA, which theoretically can detect any organism (e.g.,
Finkbeiner et al., 2008). However, studies to date have often
relied on the DNA sequencing of 16S rRNA genes of bacteria.
This standard and reliable method has identified dysbiosis in
IBD and T1D (Wen et al., 2008; Roesch et al., 2009; Giongo
et al., 2011; Sartor, 2008; Garrett et al., 2010b). Whether these
changes are causal or secondary to disease is unclear.
An outstanding example of consequences of relying on the
analysis of only a subset of the metagenome is the recent appre-
ciation that bacterial phage viruses are amajor and dynamic part
of the intestinal microbiome (Reyes et al., 2010). This adds an
enteric bacterial ‘‘virome’’ to the eukaryotic virome that lives in
our tissues (Virgin et al., 2009). Bacteria are not the only cells,
in addition to host cells, that can be infected by viruses with
consequent changes in biology. For example, an RNA virus
infects the eukaryotic pathogen Leishmania and regulates the
host inflammatory responses during parasite infection (Ives
et al., 2011). Thus, like bacteria and their phages, all Eukarya in
the microbiome are candidates for viral infection that might alter
biological processes.
The tools to detect and quantify the entire non-host metage-
nome at a reasonable cost will undoubtedly develop rapidly as
metagenomic sequencing technologies and computational
approaches to phylogeny and microbe detection are developed
and applied. Similarly, sequencing the entire host genome is
becoming more cost efficient and practical. This wealth of data
will set the stage for metagenetics, but meaningful and robust
analyses of the complex interactions within the metagenome
will require new computational tools and new conceptualizations
of gene-gene and gene-microbe interactions.
Conclusion: The Metagenetics of Mechanism-Based
Disease Subtypes
Here we have argued that two factors need to be considered as
key contributors to the genetics and pathogenesis of complex
inflammatory diseases, such as T1D, CD, and UC: specific
host-gene-microbial interactions and the mechanistic heteroge-
neity of phenotypes that constitute complex diseases. Although
we have used the lens of T1D, CD, and UC research to support
these concepts, it is clear that these ideasmay apply to a broader
array of diseases as well. The striking effects of the microbiome
on systemic immunity and on diseases that affect both visceral
and mucosal tissues suggest that any physiologic process
may be altered by the microbiome and gene-specific interac-
tions of the microbiome with the host. At a minimum, the diverse
diseases that have been revealed by GWAS to share risk alleles
are strong candidates for considering the metagenome, rather
than only the host genome, as contributing to health or disease.
The concepts of mechanism-defined disease subtypes and
host-gene-microbial interactions cooperate in important ways.
For example, if the single diagnosis of CD or T1D includes mul-
tiple mechanistic phenotypes (Figure 2 and Figure 3), a specific
host-gene-microbial interaction (Figure 4) might contribute to
only one of these phenotypes. In this setting, the impact of inter-
actions between genes in themetagenome, of either microbial or
host origin, would be obscured. This could, for example, obscure
the role of a single microbe in causing one mechanism-based
disease subtype rather than causing all cases of a disease.
Failure to identify such an agent would prevent the use of
approaches that treat or vaccinate against the agent (Figure 2
and Figure 5). It is logical and anticipated that stratifying patients
for treatment with pathway-specific drugs will improve out-
comes and success of phase II and III clinical trials (Figure 3).
This paradigm is highly effective and increasingly used in the
treatment of cancer, but it also seems likely to benefit those
with germline-based predisposition to disease as well.
Deconvoluting the complex matrix of interactions within the
metagenome that contribute to disease will require more com-
plete analyses of the metagenome. It also requires an iterative
redefinition of disease subtypes using markers that distinguish
between patients based on the mechanism responsible for injury
rather than the presence of tissue injury per se. This ambitious
goal is daunting to consider, but data discussed herein from
human studies, animal studies, and analyses of the microbiome
lead us to the inescapable conclusion that complex interactions
within the metagenome control phenotypes. We must face thiscomplexity head-on to solve the puzzle of the etiology and path-
ogenesis of complex diseases.
We, therefore, argue for the inclusion of the metagenome in
human genetic studies for these diseases. We view complex
diseases as ‘‘metagenetic,’’ reflecting the contributions of both
host and non-host genes within the metagenome. The non-
host genes in the metagenome that are relevant to a disease
might be viral, bacterial, or derived from additional members of
the microbiome, which are still largely uncharacterized. Para-
sites likely play a critical role in some populations. These meta-
genetic interactions probably contribute to the development of
disease at two levels (Figure 5). First, we envision the normal
immune system developing via harmonious relationships within
the metagenome. For example, the level of innate immunity in
mice is regulated by chronic herpesvirus infection (Barton
et al., 2007; White et al., 2010), and therefore acquisition of
a specific chronic virus might predispose the host to either help-
ful or harmful responses to other components of themicrobiome.
It will be important to develop quantitative and robust ways to in-
dentify such a ‘‘normal’’ immune system. Second, once a poorly
balanced immune system is generated, host gene interactions,
with either other host genes or the non-host metagenome, likely
synergize to generate inappropriate levels of inflammation in
response to microbial products (e.g., CD and UC) or to set the
stage for development of HLA-dependent autoimmunity (T1D).
Understanding this level of biological complexity will require
the involvement of statisticians, computational biologists, genet-
icists, pathogenesis experts, virologists, bacteriologists, and
parasitologists in an integrated fashion to identify mechanisti-
cally important interactions. Such an integrated approach can
then perhaps make sense of the metagenetics of complex
diseases, to the advantage of us all.
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